Cerus Corp
F:CU2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cerus Corp
F:CU2
|
US |
|
Olvi Oyj
LSE:0FHS
|
FI |
|
Italgas SpA
MIL:IG
|
IT |
|
K
|
KME Group SpA
F:MTJ3
|
IT |
|
P
|
Public Service Enterprise Group Inc
DUS:PSE
|
US |
|
G
|
Garmin Ltd
XHAM:GEY
|
CH |
Earnings Calls
Last Earnings Call
Revenue: Cerus posted second-quarter product revenue of $57.4 million, up 10% year over year, and said demand remained strong across product categories.
Guidance: Management raised full-year 2026 product revenue guidance to $229 million to $231 million and lifted IFC revenue guidance to $23 million to $25 million.
IFC Growth: U.S. IFC revenue reached $6.7 million, and management said kit adoption, BCA partnerships, and hospital activations are driving momentum.
Margins: Product gross margin was 51.4%, pressured by a stronger euro and inflation, but management still expects 2026 gross margins to stay in the low 50s.
Pipeline: Cerus submitted the INT200 platelet PMA to the FDA and remains on track for top-line RedeS red blood cell data in the fourth quarter.
Balance Sheet: A debt refinancing reduced term debt by $30 million and is expected to cut annual interest expense by up to $3.5 million.